Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
UARK 2003-33, Total Therapy III
This study is currently recruiting patients.
Sponsored by: | University of Arkansas
Millennium Pharmaceuticals
Celgene Corporation
|
---|---|
Information provided by: | University of Arkansas |
Purpose
There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total Therapy II (from 1996 to 2004). Results have shown that patients treated on these studies had better outcomes (meaning patients have lived longer and had better responses to treatment) when compared to patients treated with standard chemotherapy.
With this new study, Total Therapy III, researchers will take what they have learned from the first two studies and add new treatment strategies to try to improve the outcomes even more, especially for patients with chromosome abnormalities.
Condition | Treatment or Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: Velcade Drug: Thalidomide |
Phase III |
MedlinePlus related topics: Multiple Myeloma
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Efficacy Study
Official Title: A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib into Tandem Melphalan-Based Autotransplants with DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance
Expected Total Enrollment: 300
Study start: January 2004
Eligibility
Ages Eligible for Study: 18 Years - 75 Years, Genders Eligible for Study: Both
Criteria
Induction Inclusion Criteria:
Induction Exclusion Criteria:
Location and Contact Information
More Information
Click here for more information about UAMS
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |